Novartis(NYSE:NVS) 
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology,...
Website: http://www.novartis.com
Founded: 1996
Full Time Employees: 110,000
Sector: Healthcare
Industry: Drug Manufacturers-General
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-09-30 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-09-30 | 2010-04-20 | 2010-02-09 | 2010-01-26 | 2009-10-22 | 2009-07-16 | 2009-04-23 | 2009-02-09 | 2009-01-28 | 2008-10-20 | 2008-07-17 | 2008-04-21 | 2008-02-08 | 2008-01-22 | 2007-10-19 | 2007-07-17 | 2007-04-26 | 2007-02-14 | 2007-01-24 | 2006-10-24 | 2006-07-18 | 2006-04-27 | 2006-02-08 | 2006-01-20 | 2005-12-31 | 2005-10-19 | 2005-07-21 | 2005-04-22 | 2005-02-04 | 2005-01-20 | 2004-10-22 | 2004-07-20 | 2004-02-06 | 2003-12-31 | 2002-12-31 | 2002-02-22 | 2001-12-31 |
|---|
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2024-12-31 | 2023-12-31 | 2021-12-31 | 2020-12-31 | 2019-09-30 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-09-30 | 2010-03-31 | 2009-12-31 | 2009-10-22 | 2009-06-30 | 2009-03-31 | 2009-02-09 | 2008-12-31 | 2008-10-20 | 2008-06-30 | 2008-03-31 | 2007-12-31 | 2007-10-19 | 2007-07-17 | 2007-06-30 | 2007-04-26 | 2007-03-31 | 2006-12-31 | 2006-10-24 | 2006-06-30 | 2006-03-31 | 2006-02-14 | 2005-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | |||||||||||||||||||||||||||||||||||
non-current assets | 102,000,000 | 110,000,000 | |||||||||||||||||||||||||||||||||
property, plant and equipment | 9,000,000 | 9,000,000 | 11,000,000 | 11,000,000 | |||||||||||||||||||||||||||||||
right-of-use assets | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | |||||||||||||||||||||||||||||||
goodwill | 24,000,000 | 23,000,000 | 29,000,000 | 26,000,000 | 31,000,000 | 30,000,000 | 29 | 30 | 30 | 30 | 29 | 11 | 12 | 11 | 11 | 10 | 12,000,000 | 11 | |||||||||||||||||
intangible assets other than goodwill | 26,000,000 | 26,000,000 | 34,000,000 | 29,000,000 | 29,000,000 | 31,000,000 | 31 | 33 | 34 | 34 | 35 | 10,000,000 | |||||||||||||||||||||||
investments in associated companies | 119,000,000 | 205,000,000 | 205,000,000 | 8,000,000 | 15,000,000 | 14,000,000 | 17,000,000 | ||||||||||||||||||||||||||||
deferred tax assets | 4,000,000 | 4,000,000 | 3,000,000 | 7,000,000 | 8,000,000 | 10,000,000 | 4,000,000 | 3,000,000 | |||||||||||||||||||||||||||
financial assets | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | ||||||||||||||||||||||||||||||
other non-current assets | 3,000,000 | 689,000,000 | 818,000,000 | 698,000,000 | |||||||||||||||||||||||||||||||
total non-current assets | 72,000,000 | 69,000,000 | 86,000,000 | 89,000,000 | 104,000,000 | 105,000,000 | 93 | 95 | 99 | 98 | 96 | 59 | 61 | 60 | 57 | 55 | 61,000,000 | 57 | 58 | 51 | 50 | 48 | 48 | 46 | 46 | 46 | 46 | 46 | 45 | 46 | 36 | 46,000,000 | 36 | ||
current assets | |||||||||||||||||||||||||||||||||||
inventories | 5,000,000 | 5,000,000 | 6,000,000 | 7,000,000 | 6,000,000 | 6,000,000 | 6,000,000 | 6,000,000 | 5 | 6 | 7 | 6 | 6 | 5 | 5 | 6 | 6 | 5 | 5,000,000 | 5 | 5 | 6 | 6 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 3 | 4,000,000 | 3 |
trade receivables | 7,000,000 | 7,000,000 | 8,000,000 | 7,000,000 | 8,000,000 | 8,000,000 | 10 | 10 | 10 | 10 | 10 | 7 | 8 | 7 | 7 | 6 | 8,000,000 | 7 | |||||||||||||||||
income tax receivables | 133,000,000 | 244,000,000 | 202,000,000 | ||||||||||||||||||||||||||||||||
marketable securities, commodities, time deposits and derivative financial instruments | 1,000,000 | 1,000,000 | 15,000,000 | 339,000,000 | 625,000,000 | 770,000,000 | |||||||||||||||||||||||||||||
cash and cash equivalents | 11,000,000 | 13,000,000 | 12,000,000 | 8,000,000 | 8,000,000 | 7,000,000 | 2,000,000 | 3,000,000 | |||||||||||||||||||||||||||
other current assets | 2,000,000 | 10,000,000 | 2,000,000 | 11,000,000 | 3,000,000 | 2,000,000 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2,000,000 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 2,000,000 | 1 | ||
total current assets | 29,000,000 | 30,000,000 | 45,000,000 | 26,000,000 | 28,000,000 | 24,000,000 | 24 | 25 | 26 | 29 | 27 | 35 | 33 | 30 | 27 | 22 | 33,000,000 | 20 | 23 | 32 | 26 | 27 | 28 | 23 | 23 | 21 | 21 | 21 | 20 | 19 | 21 | 21,000,000 | 21 | ||
total assets | 102,000,000 | 99,000,000 | 131,000,000 | 132,000,000 | 115,000,000 | 145,000,000 | 133,000,000 | 130,000,000 | 117 | 121 | 125 | 127 | 124 | 95 | 95 | 90 | 84 | 77 | 95,000,000 | 78 | 82 | 83 | 76 | 75 | 76 | 70 | 70 | 68 | 68 | 68 | 66 | 65 | 58 | 68,000,000 | 57 |
equity and liabilities | |||||||||||||||||||||||||||||||||||
equity | |||||||||||||||||||||||||||||||||||
share capital | 793,000,000 | 936,000,000 | 969,000,000 | 972,000,000 | 957,000,000 | 990,000,000 | |||||||||||||||||||||||||||||
treasury shares | -53,000,000 | -80,000,000 | -140,000,000 | ||||||||||||||||||||||||||||||||
reserves | 43,000,000 | 51,000,000 | 73,000,000 | 73,000,000 | 56,000,000 | 40,000,000 | |||||||||||||||||||||||||||||
equity attributable to novartis ag shareholders | 44,000,000 | ||||||||||||||||||||||||||||||||||
non-controlling interests | 80,000,000 | 68,000,000 | 74,000,000 | 78,000,000 | 59,000,000 | 59,000,000 | 75,000,000 | ||||||||||||||||||||||||||||
total equity | 44,000,000 | 46,000,000 | 67,000,000 | 56,000,000 | 52,000,000 | 78,000,000 | 74,000,000 | 74,000,000 | 65 | 66 | 67 | 65 | 66 | 55 | 57 | 53 | 50 | 46 | 57,000,000 | 50 | 50 | 51 | 49 | 49 | 49 | 43 | 43 | 40 | 40 | 41 | 38 | 37 | 33 | 41,000,000 | 33 |
liabilities | |||||||||||||||||||||||||||||||||||
non-current liabilities | 42,000,000 | 37,000,000 | |||||||||||||||||||||||||||||||||
financial debts | 21,000,000 | 18,000,000 | 22,000,000 | 20,000,000 | 23,000,000 | 17,000,000 | 13 | 13 | 13 | 14 | 14 | 13 | 8 | 8 | 9 | 6 | 8,000,000 | 2 | 2 | 2 | 748 | 677 | 667 | 632 | 632 | 661 | 661 | 656 | 1 | 1 | 1 | 656,000,000 | 1 | ||
lease liabilities | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | |||||||||||||||||||||||||||||||
deferred tax liabilities | 2,000,000 | 2,000,000 | 3,000,000 | 5,000,000 | 5,000,000 | 6,000,000 | 4,000,000 | 5,000,000 | |||||||||||||||||||||||||||
provisions and other non-current liabilities | 4,000,000 | 4,000,000 | 6,000,000 | 7,000,000 | 7,000,000 | 8,000,000 | 5,000,000 | 4,000,000 | |||||||||||||||||||||||||||
total non-current liabilities | 29,000,000 | 26,000,000 | 33,000,000 | 35,000,000 | 35,000,000 | 33,000,000 | 28 | 29 | 29 | 29 | 30 | 23 | 18 | 19 | 18 | 16 | 18,000,000 | 11 | 11 | 12 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 11 | 12 | 9 | 10,000,000 | 9 | ||
current liabilities | |||||||||||||||||||||||||||||||||||
trade payables | 4,000,000 | 4,000,000 | 5,000,000 | 4,000,000 | 5,000,000 | 4,000,000 | 4 | 4 | 4 | 4 | 3 | 3 | 4 | 3 | 3 | 3 | 4,000,000 | 3 | |||||||||||||||||
financial debts and derivative financial instruments | 8,000,000 | 6,000,000 | 6,000,000 | 8,000,000 | 5,000,000 | 5,000,000 | 5,000,000 | 6,000,000 | |||||||||||||||||||||||||||
current income tax liabilities | 1,000,000 | 2,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | |||||||||||||||||||||||||||||
provisions and other current liabilities | 14,000,000 | 12,000,000 | 11,000,000 | 9,000,000 | 8,000,000 | 5,000,000 | |||||||||||||||||||||||||||||
total current liabilities | 28,000,000 | 26,000,000 | 30,000,000 | 28,000,000 | 23,000,000 | 22,000,000 | 23 | 25 | 29 | 32 | 27 | 17 | 19 | 17 | 15 | 14 | 19,000,000 | 16 | 19 | 19 | 17 | 16 | 17 | 17 | 17 | 17 | 17 | 16 | 16 | 16 | 15 | 16,000,000 | 15 | ||
total liabilities | 58,000,000 | 53,000,000 | 63,000,000 | 75,000,000 | 63,000,000 | 66,000,000 | 58,000,000 | 55,000,000 | 51 | 55 | 58 | 61 | 58 | 40 | 38 | 37 | 33 | 31 | 38,000,000 | 27 | 31 | 31 | 27 | 26 | 27 | 26 | 26 | 27 | 27 | 26 | 28 | 28 | 25 | 26,000,000 | 24 |
total equity and liabilities | 102,000,000 | 99,000,000 | 131,000,000 | 115,000,000 | 133,000,000 | 130,000,000 | 117 | 121 | 125 | 127 | 124 | 95 | 95 | 90 | 84 | 77 | 95,000,000 | 78 | 82 | 83 | 76 | 75 | 76 | 70 | 70 | 68 | 68 | 68 | 66 | 65 | 58 | 68,000,000 | 57 | ||
the accompanying notes form an integral part of the consolidated financial statements. | |||||||||||||||||||||||||||||||||||
financial assets and other non-current assets | 3,000,000 | 5,000,000 | |||||||||||||||||||||||||||||||||
other current assets and income tax receivables | 3,000,000 | 2,000,000 | |||||||||||||||||||||||||||||||||
provisions and other current liabilities and current income tax liabilities | 15,000,000 | 18,000,000 | |||||||||||||||||||||||||||||||||
1 the december 31, 2020 deferred tax assets and deferred tax liabilities balances have been adjusted to conform with the 2021 presentation, see “item 18. financial statements–note 12. deferred tax assets and liabilities.” | |||||||||||||||||||||||||||||||||||
balance sheet data | |||||||||||||||||||||||||||||||||||
cash, cash equivalents, and marketable securities and derivative financial instruments | 11,000,000 | ||||||||||||||||||||||||||||||||||
assets of disposal group held for sale1 | 807,000,000 | ||||||||||||||||||||||||||||||||||
trade accounts payable | 5,000,000 | 5,000,000 | 2 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2,000,000 | 1 | ||||||||||||||||||
other current liabilities | 27,000,000 | 24,000,000 | 11 | 11 | 11 | 11 | 11 | 9 | 10 | 8 | 7 | 7 | 7 | 8 | 7 | 8 | 8 | 8 | 6 | 6 | 8 | 8 | 6 | 6 | 6 | 6 | 6 | ||||||||
liabilities of disposal group held for sale1 | 51,000,000 | ||||||||||||||||||||||||||||||||||
equity attributable to shareholders of novartis ag | 56,000,000 | ||||||||||||||||||||||||||||||||||
total liabilities and equity | 132,000,000 | 145,000,000 | |||||||||||||||||||||||||||||||||
net assets | 56,000,000 | 78,000,000 | |||||||||||||||||||||||||||||||||
outstanding share capital | 860,000,000 | 875,000,000 | |||||||||||||||||||||||||||||||||
total outstanding shares | 2,000,000 | 2,000,000 | |||||||||||||||||||||||||||||||||
1 in 2019 and 2018, the disposal group held for sale related to the assets and liabilities of the planned divestment of the sandoz us dermatology business and generic us oral solids portfolio to aurobindo pharma usa inc., as announced on september 6, 2018. in march 2020, novartis took the decision to retain these businesses. (see “item 18. financial statements—note 2. significant transactions"). | |||||||||||||||||||||||||||||||||||
assets of disposal group held for sale | 845,000,000 | ||||||||||||||||||||||||||||||||||
issued share capital and reserves attributable to novartis ag shareholders | 52,000,000 | 74,000,000 | 74,000,000 | 57,000,000 | |||||||||||||||||||||||||||||||
liabilities of disposal group held for sale | 24,000,000 | ||||||||||||||||||||||||||||||||||
cash, cash equivalents and marketable securities & derivative financial instruments | 15,000,000 | ||||||||||||||||||||||||||||||||||
assets related to discontinued operations2 | |||||||||||||||||||||||||||||||||||
liabilities related to discontinued operations2 | |||||||||||||||||||||||||||||||||||
issued share capital and reserves attributable to shareholders of novartis ag | 78,000,000 | 41,000,000 | |||||||||||||||||||||||||||||||||
1 the disposal group held for sale relate to the assets and liabilities of the pending divestment of the sandoz us dermatology business and generic us oral solids portfolio to aurobindo pharma usa inc., as announced on september 6, 2018 (see “item 18. financial statements – note 2 significant pending transactions). | |||||||||||||||||||||||||||||||||||
2 a description of discontined operations can be found in footnote 1 of the table above. | |||||||||||||||||||||||||||||||||||
property, plant & equipment | 16,000,000 | 15,000,000 | 15 | 16 | 16 | 16 | 15 | 13 | 14 | 13 | 13 | 12 | 14,000,000 | 13 | 12 | 13 | 13 | 12 | 12 | 11 | 11 | 10,000,000 | |||||||||||||
financial and other non-current assets | 15 | 16 | 17 | 16 | 15 | 24 | 25 | 24 | 23 | 22 | 23 | 24 | 16 | 14 | 14 | 15 | 14 | 14 | 4,000,000 | ||||||||||||||||
cash, short-term deposits and marketable securities | 5 | 5 | 5 | 8 | 7 | 19 | 17 | 14 | 11 | 7 | 6 | 8 | 16 | 10 | 13 | 14 | 7 | 7 | 6 | 6 | 7 | 8 | 7 | 11 | 10 | ||||||||||
other non-current liabilities | 14 | 15 | 15 | 15 | 16 | 9 | 9 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 9 | 8 | 8 | 9 | 9 | 9 | 9 | 10 | 8 | 7 | ||||||||||
financial debts and derivatives | 6 | 10 | 13 | 16 | 12 | 4 | 5 | 5 | 4 | 4 | 5 | 8 | 8 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 6 | 7 | ||||||||||
intangibles other than goodwill | 9 | 10 | 10 | 9 | |||||||||||||||||||||||||||||||
other intangible assets | 9 | 9 | |||||||||||||||||||||||||||||||||
other non-current non-financial assets | 328,000,000 | ||||||||||||||||||||||||||||||||||
marketable securities and derivative financial instruments | 14,000,000 | ||||||||||||||||||||||||||||||||||
intangible assets | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21,000,000 | |||||||||||||||||||||||||||
trade accounts receivable | 7 | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 6,000,000 | 5 | ||||||||||||||||||||
total current assets from continuing operations | 32 | 26 | 27 | 28 | 20 | 20 | 20 | 20 | 20 | 20,000,000 | |||||||||||||||||||||||||
assets held for sale related to discontinued operations | |||||||||||||||||||||||||||||||||||
total current liabilities from continuing operations | 19 | 17 | 16 | 17 | 15 | 15 | 17 | 17 | 16 | 16,000,000 | |||||||||||||||||||||||||
liabilities related to discontinued operations | |||||||||||||||||||||||||||||||||||
assets related to discontinued operations | |||||||||||||||||||||||||||||||||||
assets related to discontinuing operations | 3 | 3 | 750 | 750 | 736 | 736,000,000 | |||||||||||||||||||||||||||||
liabilities related to discontinuing operations | 1 | 1 | 182 | 182 | 207 | 207,000,000 | |||||||||||||||||||||||||||||
associated companies | 6,000,000 | ||||||||||||||||||||||||||||||||||
marketable securities & derivative financial instruments | 4,000,000 | ||||||||||||||||||||||||||||||||||
minority interests | 183,000,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2019-09-30 |
|---|---|
net cash flows from operating activities from continuing operations | 4,000,000 |
net cash flows from operating activities from discontinued operations | |
net cash flows (used in)/from investing activities from continuing operations | |
net cash flows used in investing activities from discontinued operations | |
net cash flows used in financing activities from continuing operations | |
net cash flows from financing activities from discontinued operations | |
effect of exchange rate changes on cash and cash equivalents | -64,000,000 |
net change in cash and cash equivalents | |
change in marketable securities, commodities, time deposits and derivative financial instruments | |
change in current and non-current financial debts and derivative financial instruments | |
change in net debt | |
net debt at january 1 | |
net debt at december 31 | |
net sales from continuing operations | |
other revenues | |
cost of goods sold | |
gross profit from continuing operations | |
selling, general and administration | |
research and development | |
other income | |
operating income from continuing operations | |
return on net sales | |
income from associated companies | |
interest expense | |
other financial income and expense | |
income before taxes from continuing operations | |
income taxes | |
net income from continuing operations | 2,000,000 |
net income from discontinued operations before gain on distribution of sandoz group ag to novartis ag shareholders | |
gain on distribution of sandoz group ag to novartis ag shareholders | |
net income from discontinued operations | |
net income | |
basic earnings per share from continuing operations | |
basic earnings per share from discontinued operations | |
total basic earnings per share | |
non-ifrs measures 2 | |
free cash flow from continuing operations 2, 3 | |
1 for information on continuing operations and discontinued operations, refer to the overview section above in this item 5 and "item 18. financial statements—note 1. accounting policies ", "item 18. financial statements—note 2. significant transactions—significant transactions in 2023," and "item 18. financial statements—note 31. discontinued operations." | |
2 for an explanation of non-ifrs measures and reconciliation tables, see "—non-ifrs measures as defined by novartis." | |
3 effective january 1, 2023, novartis revised its definition of free cash flow, to define free cash flow as net cash flows from operating activities less purchases of property, plant and equipment. to aid in comparability, the prior year free cash flow amounts have been revised to conform with the new free cash flow definition. see "—non-ifrs measures as defined by novartis" | |
nm = not meaningful | |
cardiovascular, renal and metabolic | |
immunology | |
neuroscience | |
oncology | |
total promoted brands | |
established brands 3 | |
total net sales from continuing operations 3 | |
1 reclassified to conform with the 2023 organizational structure. | |
3 effective january 1, 2023, the discontinued operations sandoz business bio-technology manufacturing services to other companies’ activities and the coartem brand were transferred to the novartis continuing operations. the financial information of the novartis continuing operations and discontinued operations were adapted accordingly in 2022, in compliance with ifrs accounting standards. see “item 18. financial statements – note 3. operating segment.” | |
net cash flows from/used in investing activities from continuing operations | |
net cash flows used in financing activities from discontinued operations | |
net sales to third parties from continuing operations | |
sales to discontinued operations | |
% of net sales to third parties | |
taxes | |
net income from discontinued operations before gain on distribution of alcon inc. to novartis ag shareholders | |
gain on distribution of alcon inc. to novartis ag shareholders | |
attributable to: | |
shareholders of novartis ag | |
non-controlling interests | |
free cash flow from continuing operations 2 | |
1 continuing operations include the businesses of the innovative medicines and sandoz divisions and the continuing corporate activities and discontinued operations include the alcon eye care devices business and certain corporate activities attributable to the alcon business prior to the spin-off, the gain on distribution of alcon inc. to novartis ag shareholders in 2019 and certain other incomes related to the distribution. see “item 18. financial statements—note 1. significant accounting policies”, “item 18. financial statements—note 2. significant transactions—significant transactions in 2019,” and “item 18. financial statements—note 30. discontinued operations.” | |
2 for an explanation of non-ifrs measures and reconciliation tables, see "item 5.a operating results—non-ifrs measures as defined by novartis." | |
innovative medicines | |
sandoz | |
adjustments to reconcile net income from continuing operations to net cash flows from operating activities from continuing operations | |
reversal of non-cash items and other adjustments | 2,000,000 |
dividends received from associated companies and others | |
interest received | 32,000,000 |
interest paid | -134,000,000 |
other financial receipts | 51,000,000 |
other financial payments | -9,000,000 |
taxes paid1 | -235,000,000 |
net cash flows from operating activities from continuing operations before working capital and provision changes | 4,000,000 |
payments out of provisions and other net cash movements in non-current liabilities | -146,000,000 |
change in net current assets and other operating cash flow items | 691,000,000 |
net cash flows from operating activities from discontinued operations 1 | |
total net cash flows from operating activities | 4,000,000 |
purchase of property, plant and equipment | -357,000,000 |
proceeds from sales of property, plant and equipment | -3,000,000 |
purchase of intangible assets | -205,000,000 |
proceeds from sales of intangible assets | 140,000,000 |
purchase of financial assets | -69,000,000 |
proceeds from sales of financial assets | 565,000,000 |
purchase of other non-current assets | -10,000,000 |
proceeds from sales of other non-current assets | 1,000,000 |
acquisitions of interests in associated companies, net1 | -1,000,000 |
acquisitions and divestments of businesses | -3,000,000 |
purchase of marketable securities and commodities | -69,000,000 |
proceeds from sales of marketable securities and commodities | 67,000,000 |
net cash flows from investing activities from continuing operations | -3,000,000 |
net cash flows from/used in investing activities from discontinued operations 2 | 3,000,000 |
total net cash flows from investing activities | -3,000,000 |
acquisition of treasury shares | -2,000,000 |
proceeds from exercise of options and other treasury share transactions | 5,000,000 |
increase in non-current financial debts | 93,000,000 |
repayments of non-current financial debts | -186,000,000 |
change in current financial debts | 423,000,000 |
payments of lease liabilities | -92,000,000 |
receipts from finance sublease receivables | 7,000,000 |
impact of change in ownership of consolidated entities | -1,000,000 |
dividends paid to non-controlling interests and other financing cash flows | -2,000,000 |
net cash flows from financing activities from continuing operations | -2,000,000 |
net cash flows from financing activities from discontinued operations 3 | -20,000,000 |
total net cash flows from financing activities | -2,000,000 |
net change in cash and cash equivalents before effect of exchange rate changes | -1,000,000 |
total net change in cash and cash equivalents | -1,000,000 |
cash and cash equivalents at july 1 | 9,000,000 |
cash and cash equivalents at september 30 | 8,000,000 |
1 in q3 2018, the total net tax payment amounted to usd 336 million, of which usd 75 million was included in the line "acquisitions of interests in associated companies, net" and usd 42 million was included in the line “net cash flows from operating activities from discontinued operations.” | |
2 for additional information related to q3 2019 "net cash flows from/used in investing activities from discontinued operations", refer to note 11. | |
3 including usd 20 million | |
net sales to third parties | |
gross profit | |
operating income | |
income before taxes | |
basic earnings per share | |
net cash flows from operating activities | |
free cash flow 1 | |
1 for an explanation of non-ifrs measures and reconciliation tables, see " —item 5.a operating results—non-ifrs measures as defined by novartis." | |
alcon | |
1 restated to reflect the product transfers between divisions that was effective as of january 1, 2018. | |
net sales | |
as a % of sales | |
core operating income | |
operating income/loss | |
corporate | |
total group | |
eps | |
cash flows from operating activities | |
free cash flow | |
1 restated to reflect the product transfers between innovative medicines and alcon divisions, announced on october 24, 2017 and january 24, 2018. | |
index | |
group and divisional operating performance q1 2018 | |
group | |
cash flow and group balance sheet | |
innovation review | |
condensed interim consolidated financial statements | |
consolidated income statements | |
consolidated statements of comprehensive income | |
consolidated balance sheets | |
consolidated statement of changes in equity | |
consolidated statements of cash flow | |
notes to condensed interim consolidated financial statements, including update on legal proceedings | |
supplementary information | |
core results | |
reconciliation from ifrs to core results | |
additional information | |
condensed consolidated changes in net debt / share information | |
currency translation rates | |
disclaimer | |
reversal of non-cash items | |
taxes paid 1 | |
cash flows before working capital and provision changes from continuing operations | |
cash flows from operating activities from continuing operations | |
cash flows used in operating activities from discontinued operations 1 | |
total cash flows from operating activities | |
purchase of property, plant & equipment | |
proceeds from sales of property, plant & equipment | |
divestments of interests in associated companies | |
cash flows used in investing activities from continuing operations | |
cash flows used in/from investing activities from discontinued operations 1 | |
total cash flows used in investing activities | |
dividends paid to shareholders of novartis ag | |
proceeds from exercise options and other treasury share transactions | |
repayment of non-current financial debts | |
cash flows used in financing activities | |
cash and cash equivalents at january 1 | |
cash and cash equivalents at december 31 | |
the accompanying notes form an integral part of the consolidated financial statements. | |
1 in 2016, the total net tax payment amounted to usd 2 299 million, of which usd 188 million was included in the cash flows used in investing activities from discontinued operations. | |
in 2015, the total net tax payment amounted to usd 3 325 million, of which a refund of usd 94 million was included in the cash flows used in operating activities from discontinued operations, and a usd 965 million payment in the cash flows from investing activities of discontinued operations. | |
total cash flows used in/from investing activities | |
1 in 2016, the total net tax payment amounted to usd 2 299 million, of which usd 188 million was included in the cash flows used in investing activities from discontinued operations. in 2015, the total net tax payment amounted to usd 3 325 million, of which a refund of usd 94 million was included in the cash flows used in operating activities from discontinued operations, and a usd 965 million payment in the cash flows from investing activities of discontinued operations. in 2014, the total net tax payment amounted to usd 2 645 million, of which usd 7 million was included in the cash flows used in operating activities from discontinued operations, and a usd 459 million payment in the cash flows from investing activities from discontinued operations. | |
depreciation, amortization and impairments | |
change in provisions and other non-current liabilities | |
net financial income | |
other | |
net income adjusted for non-cash items | |
interest and other financial receipts | |
interest and other financial payments | |
taxes paid | |
cash flows before working capital changes | |
purchase of intangible, financial and other non-current assets | |
proceeds from sales of property, plant & equipment, intangible, financial and other non-current assets | |
change in marketable securities and investment in associated companies | |
cash flows used in investing activities | |
change in current and non-current financial debts | |
treasury share transactions | |
acquisition of alcon non-controlling interests | |
other financing cash flows | |
translation effect on cash and cash equivalents | |
change in cash and cash equivalents | |
cash and cash equivalents at october 1 | |
acquisitions and divestments of subsidiaries | |
change in marketable securities | |
cash flows used in / from financing activities | |
net financial expense/income | |
cash flow before working capital changes | |
cash flow from operating activities | |
investments in property, plant & equipment | |
investments in intangible, financial and other non-current assets | |
sale of property, plant & equipment, intangible, financial and other non-current assets | |
acquisitions of subsidiaries | |
increase in marketable securities, associated companies and non-controlling interests | |
cash flow used for investing activities | |
cash flow from financing activities | |
cash and cash equivalents at march 31 | |
cash flow from operating activities from continuing operations | |
investments in intangible, non-current and financial assets | |
acquisitions / divestments | |
cash flow from investing activities from continuing operations | |
cash flow from financing activities from continuing operations | |
cash flow from discontinued operations | |
decrease/increase in marketable securities, intangible and financial assets | |
treasury share transactions and other financing cash flows | |
change in cash and cash equivalents from discontinued operations | |
change in cash and cash equivalents from continuing operations | |
cash and cash equivalents at january 1 from continuing operations | |
cash and cash equivalents at june 30 from continuing operations | |
cash and cash equivalents at march 31 from continuing operations | |
restructuring payments and other cash payments out of provisions | |
cash flow from operating activities of continuing operations | |
increase in marketable securities, intangible and financial assets | |
cash flow from investing activities of continuing operations | |
cash flow from financing activities of continuing operations | |
cash and cash equivalents from continuing operations at january 1 | |
cash and cash equivalents from continuing operations at september 30 | |
cash flow before working capital and provision changes | |
cash flow from discontinuing operations | |
change in cash and cash equivalents from discontinuing operations | |
cash and cash equivalents from continuing operations at june 30 | |
acquisitions/divestments of subsidiaries | |
cash flow used for financing activities | |
cash and cash equivalents at sept 30 | |
cash and cash equivalents at june 30 | |
depreciation, amortization and impairments on | |
property, plant & equipment | |
intangible assets | |
financial assets | |
divestment loss/gain from disposal of subsidiaries | |
gains on disposal of property, plant & equipment, intangible and financial assets | |
equity settled share-based compensation expense | |
total reversal of non-cash items | |
dividends from associated companies | |
dividends received from marketable securities | |
cash flow before working capital and provision changes from continuing operations | |
proceeds from disposals of property, plant & equipment | |
proceeds from disposals of intangible assets | |
proceeds from disposals of financial assets | |
acquisition of additional interests in associated companies | |
acquisition of minority interests | |
proceeds from disposals of marketable securities | |
purchase of marketable securities | |
cash flow used for investing activities of continuing operations | |
acquisition or disposal of treasury shares | |
proceeds from issuance of share capital to third parties by subsidiaries | |
withholding tax recoverable | |
dividend payments and cash contributions to minority interests | |
cash flow used for financing activities of continuing operations | |
net effect of currency translation on cash and cash equivalents | |
cash and cash equivalents at the end of the year of discontinuing operations | |
net change in cash and cash equivalents of continuing operations | |
cash and cash equivalents at the beginning of the year | |
cash and cash equivalents at the end of the year of continuing operations | |
cash and cash equivalents at year-end for discontinuing operations | |
cash and cash equivalents for continuing operations at december 31 |